Portal de investigación
- Inicio
- Proyectos y Estudios
- : A Phase II, Open-Label Randomized Study of Intravenous Tambiciclib in Combination with the standard of care Venetoclax and Azacitidine in Patients with Newly Diagnosed AML Who Failed to Achieve at Least MLFS After the First Two Cycles of Treatment with Venetoclax and Azacitidine Alone.
: A Phase II, Open-Label Randomized Study of Intravenous Tambiciclib in Combination with the standard of care Venetoclax and Azacitidine in Patients with Newly Diagnosed AML Who Failed to Achieve at Least MLFS After the First Two Cycles of Treatment with Venetoclax and Azacitidine Alone.
Datos básicos
Documentos
- No hay documentos
Participantes
Grupos
Financiadores - Promotores
FUNDACIÓN PARA LA INVESTIGACIÓN DEL HOSPITAL UNIVERSITARIO LA FE DE LA COMUNIDAD VALENCIANA
ISTITUTO ROMAGNOLO PER LO STUDIO DEI TUMORI "DINO AMADORI" - IRST S.R.L.
SELLAS LIFE SCIENCES
Cita
: A Phase II, Open-Label Randomized Study of Intravenous Tambiciclib in Combination with the standard of care Venetoclax and Azacitidine in Patients with Newly Diagnosed AML Who Failed to Achieve at Least MLFS After the First Two Cycles of Treatment with Venetoclax and Azacitidine Alone. (IMPACT-SURPASS study). FUNDACIÓN PARA LA INVESTIGACIÓN DEL HOSPITAL UNIVERSITARIO LA FE DE LA COMUNIDAD VALENCIANA; ISTITUTO ROMAGNOLO PER LO STUDIO DEI TUMORI "DINO AMADORI" - IRST S.R.L.; SELLAS LIFE SCIENCES. 2026IP:PAU MONTESINOS FERNÁNDEZ.